News stories about Celgene (NASDAQ:CELG) have trended somewhat positive on Thursday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celgene earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.382663980714 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Biopharma company Celgene is set to acquire Impact Biomedicines (healthcareglobal.com)
- Key Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare Conference (finance.yahoo.com)
- Here's What Celgene's Management Just Said About Its Future (finance.yahoo.com)
- Yes, There’s Hope for Celgene. Really. (barrons.com)
- Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus (finance.yahoo.com)
Several equities analysts have recently weighed in on CELG shares. Bank of America reaffirmed a “buy” rating on shares of Celgene in a research note on Wednesday, September 13th. Vetr raised Celgene from a “hold” rating to a “buy” rating and set a $146.58 price objective on the stock in a research note on Friday, October 6th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $173.00 price objective on shares of Celgene in a research note on Thursday, October 5th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $162.00 price objective on shares of Celgene in a research note on Tuesday, September 26th. Finally, Robert W. Baird reaffirmed a “buy” rating and issued a $162.00 price objective on shares of Celgene in a research note on Thursday, September 21st. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $131.18.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 43.32% and a net margin of 30.06%. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the prior year, the company posted $1.58 EPS. Celgene’s quarterly revenue was up 10.2% on a year-over-year basis. sell-side analysts anticipate that Celgene will post 6.68 earnings per share for the current year.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.